rf-fullcolor.png

 

October 17, 2019
by Zachary Brennan

UK Alerts to Teva Recall of Heartburn Medicines Over Impurity Fears

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday alerted to a recall of its heartburn medicine ranitidine following similar recalls due to possible contamination with an impurity called NDMA (N-nitrosodimethylamine), which may increase the risk of cancer.

For health professionals, the MHRA says to stop supplying the products immediately and quarantine all remaining stock and return it to suppliers.

Andrew Gray, MHRA deputy director of inspections, enforcement and standards added: “Patients should keep taking their current medicines but should speak to their doctor or pharmacist if they are concerned and should seek their doctor’s advice before stopping any prescribed medicines.”

GlaxoSmithKline earlier this month also recalled all unexpired stock of four types of Zantac, which is the brand name for ranitidine.

Both the European Medicines Agency and the US Food and Drug Administration began investigating NDMA levels in ranitidine medicines last month.

Following those announcements, Sandoz announced a recall of 14 lots of its prescription ranitidine capsules because of the NDMA impurity. And Apotex voluntarily recalled, on a precautionary basis, its ranitidine medicines. Dr Reddy’s Laboratories and other generic drugmakers also suspended supplies of its ranitidine medicines worldwide as a precautionary measure.

CVS pharmacies also suspended the sale of all Zantac brand and other ranitidine products until further notice. Walgreens and Rite Aid made similar moves.
 
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.